A phase III, clinical study of KRN125
Phase 3
- Conditions
- Chemotherapy-induced neutropenia
- Registration Number
- JPRN-jRCT2080221502
- Lead Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Written informed consent
- Diagnosed with non-Hodgkin's lymphoma
- Going to receive (R) CHOP treatment regimen
- No prior chemotherapy
- ECOG PS =< 2
- Appropriate bone marrow, hepatic, renal and heart functions
Exclusion Criteria
- Complication or anamnesis of cardiac disease, such as heart
failure and severe arrhythmia
- Double cancer
- Previous bone marrow or peripheral blood stem cell
transplantation
- Primary hematologic disease such as myelodysplastic
syndrome or aplastic anemia
- Undergoing interstitial pneumonia treatment
- Previous radiotherapy within 4 weeks of enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method